|
|
伏诺拉生在治疗幽门螺杆菌感染中的研究进展
|
Abstract:
幽门螺杆菌(Hp)是一种定植于胃内的致病菌，其感染被证实与胃腺癌、慢性胃炎、消化性溃疡、黏膜相关淋巴组织淋巴瘤等多种胃肠疾病密切相关。近年来，随着耐药性的增加，Hp的根除率在不断下降，临床也在不断探索新的治疗药物。伏诺拉生(VPZ)是一种新型钾离子竞争性酸阻滞剂，表现出了比质子泵抑制剂(PPI)更显著、快速且持久的抑酸作用。因此，本文通过对VPZ的药理学机制、与PPI的比较、VPZ根除Hp方案的临床研究及安全性等方面作一综述。
Helicobacter pylori (Hp) is a pathogenic bacterium that colonizes the stomach, and its infection is closely associated with a variety of gastrointestinal diseases, including gastric adenocarci-noma, chronic gastritis, peptic ulcers, and mucosa-associated lymphoid tissue lymphoma. In recent years, the eradication rate of Hp has decreased with the increase of drug resistance, and new therapeutic agents are being explored clinically. Vonoprazan (VPZ) is a novel potassi-um-competitive acid blocker that exhibits a more significant, rapid, and long-lasting acid inhib-itory effect than PPIs. Therefore, this article reviews the pharmacological mechanism of VPZ, its comparison with PPIs, and the clinical studies and safety of the VPZ Hp eradication regimen.
| [1] | Ding, S.Z., Du, Y.Q., Lu, H., et al. (2022) Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition). Gut, 71, 238-253. https://doi.org/10.1136/gutjnl-2021-325630 |
| [2] | Zhou, X.Z., Lyu, N.H., Zhu, H.Y., et al. (2023) Large-Scale, National, Family-Based Epidemiological Study on Helicobacter pylori Infection in China: The Time to Change Practice for Related Disease Prevention. Gut, 72, 855-869.
https://doi.org/10.1136/gutjnl-2022-328965 |
| [3] | Choi, I.J., Kook, M.C., Kim, Y.I., et al. (2018) Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. New England Journal of Medicine, 378, 1085-1095. https://doi.org/10.1056/NEJMoa1708423 |
| [4] | Smyth, E.C., Nilsson, M., Grabsch, H.I., et al. (2020) Gastric Cancer. Lancet, 396, 635-648.
https://doi.org/10.1016/S0140-6736(20)31288-5 |
| [5] | Malfertheiner, P., Megraud, F., O’morain, C.A., et al. (2017) Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report. Gut, 66, 6-30. https://doi.org/10.1136/gutjnl-2016-312288 |
| [6] | Malfertheiner, P., Megraud, F., Rokkas, T., et al. (2022) Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report. Gut, 71, 1724-1762. https://doi.org/10.1136/gutjnl-2022-327745 |
| [7] | 袁耀宗. 酸相关性疾病的抑酸标准及抑酸药物选择[J]. 中华消化杂志, 2023, 43(9): 579-582. |
| [8] | Shimatani, T., Inoue, M., Kuroiwa, T., et al. (2005) Acid-Suppressive Efficacy of a Reduced Dosage of Rabeprazole: Comparison of 10 mg Twice Daily Rabeprazole with 20 mg Twice Daily Rabeprazole, 30 mg Twice Daily Lansoprazole, and 20 mg Twice Daily Omeprazole by 24-Hr Intragastric PH-Metry. Digestive Diseases and Sciences, 50, 1202-1206. https://doi.org/10.1007/s10620-005-2760-0 |
| [9] | Shimatani, T., Inoue, M., Kuroiwa, T., et al. (2006) Ac-id-Suppressive Effects of Rabeprazole, Omeprazole, and Lansoprazole at Reduced and Standard Doses: A Crossover Comparative Study in Homozygous Extensive Metabolizers of Cytochrome P4502C19. Clinical Pharmacology & Therapeutics, 79, 144-152.
https://doi.org/10.1016/j.clpt.2005.09.012 |
| [10] | Sakurai, Y., Mori, Y., Okamoto, H., et al. (2015) Ac-id-Inhibitory Effects of Vonoprazan 20mg Compared with Esomeprazole 20mg or Rabeprazole 10mg in Healthy Adult Male Subjects—A Randomised Open-Label Cross-Over Study. Alimentary Pharmacology & Therapeutics, 42, 719-730. https://doi.org/10.1111/apt.13325 |
| [11] | 葛均波, 徐永健, 王辰. 内科学[M]. 第九版. 北京: 人民卫生出版社, 2018: 358. |
| [12] | Geibel, J.P. (2005) Role of Potassium in Acid Secretion. World Journal of Gastroen-terology, 11, 5259-5265.
https://doi.org/10.3748/wjg.v11.i34.5259 |
| [13] | 何金杰, 程能能. 钾离子竞争性酸阻断剂——伏诺拉生[J]. 中国临床药学杂志, 2019, 28(3): 219-222. |
| [14] | Echizen, H. (2016) The First-In-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations. Clinical Pharmacoki-netics, 55, 409-418.
https://doi.org/10.1007/s40262-015-0326-7 |
| [15] | 曾琳, 聂刚. 新型抑酸药伏诺拉生根除幽门螺杆菌的研究进展[J]. 中国临床新医学, 2023, 16(11): 1204-1209. |
| [16] | Miftahussurur, M., Putra, B.P., Yamaoka, Y. (2020) The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals, 13, Article 276. https://doi.org/10.3390/ph13100276 |
| [17] | Hori, Y., Matsukawa, J., Takeuchi, T., et al. (2011) A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in Animals. The Journal of Pharmacology and Experimental Therapeutics, 337, 797-804. https://doi.org/10.1124/jpet.111.179556 |
| [18] | Otake, K., Sakurai, Y., Nishida, H., et al. (2016) Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438). Advances in Therapy, 33, 1140-1157. https://doi.org/10.1007/s12325-016-0345-2 |
| [19] | Mori, H. and Suzuki, H. (2019) Role of Acid Suppression in Acid-Related Diseases: Proton Pump Inhibitor and Potassium-Competitive Acid Blocker. Journal of Neurogastroenterology and Motility, 25, 6-14.
https://doi.org/10.5056/jnm18139 |
| [20] | Jenkins, H., Jenkins, R. and Patat, A. (2017) Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. Clinical Drug Investigation, 37, 311-316. https://doi.org/10.1007/s40261-016-0488-6 |
| [21] | Jenkins, H., Sakurai, Y., Nishimura, A., et al. (2015) Ran-domised Clinical Trial: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Doses of TAK-438 (Vonoprazan), a Novel Potassium-Competitive Acid Blocker, in Healthy Male Subjects. Alimentary Pharmacology & Therapeutics, 41, 636-648. https://doi.org/10.1111/apt.13121 |
| [22] | Kagami, T., Sahara, S., Ichikawa, H., et al. (2016) Potent Acid Inhibition by Vonoprazan in Comparison with Esomeprazole, with Refer-ence to CYP2C19 Genotype. Alimentary Pharmacology & Therapeutics, 43, 1048-1059.
https://doi.org/10.1111/apt.13588 |
| [23] | Yang, X.X., Li, Y.Y., Sun, Y.Y., et al. (2018) Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Digestive Diseases and Sciences, 63, 302-311. https://doi.org/10.1007/s10620-017-4866-6 |
| [24] | Murakami, K., Sakurai, Y., Shiino, M., et al. (2016) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, as a Component of First-Line and Second-Line Triple Therapy for Helicobacter pylori Eradication: A Phase III, Randomised, Double-Blind Study. Gut, 65, 1439-1346. https://doi.org/10.1136/gutjnl-2015-311304 |
| [25] | Rokkas, T., Gisbert, J.P., Malfertheiner, P., et al. (2021) Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-Analysis. Gastroenterology, 161, 495-507.E4.
https://doi.org/10.1053/j.gastro.2021.04.012 |
| [26] | Li, M., Oshima, T., Horikawa, T., et al. (2018) Systematic Review with Meta-Analysis: Vonoprazan, a Potent Acid Blocker, Is Superior to Proton-Pump Inhibitors for Erad-ication of Clarithromycin-Resistant Strains of Helicobacter pylori. Helicobacter, 23, e12495. https://doi.org/10.1111/hel.12495 |
| [27] | Bunchorntavakul, C. and Buranathawornsom, A. (2021) Randomized Clinical Trial: 7-Day Vonoprazan-Based versus 14-Day Omeprazole-Based Triple Therapy for Helicobacter pylori. Journal of Gastroenterology and Hepatology, 36, 3308-3313. https://doi.org/10.1111/jgh.15700 |
| [28] | Hou, X.H., Meng, F.D., Wang, J.B., et al. (2022) Vonoprazan Non-Inferior to Lansoprazole in Treating Duodenal Ulcer and Eradicating Helicobacter pylori in Asian Patients. Journal of Gastroenterology and Hepatology, 37, 1275-1283. https://doi.org/10.1111/jgh.15837 |
| [29] | Huh, K.Y., Chung, H., Kim, Y.K., et al. (2022) Evaluation of Safety and Pharmacokinetics of Bismuth-Containing Quadruple Therapy with Either Vonoprazan or Lansoprazole for Helicobacter pylori Eradication. British Journal of Clinical Pharmacology, 88, 138-144. https://doi.org/10.1111/bcp.14934 |
| [30] | Lu, L.F., Wang, Y.J., Ye, J., et al. (2023) Quadruple Therapy with Vonoprazan 20 mg Daily as a First-Line Treatment for Helicobacter pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial. Helicobacter, 28, e12940. https://doi.org/10.1111/hel.12940 |
| [31] | Suzuki, S., Esaki, M., Kusano, C., et al. (2019) Development of Hel-icobacter pylori Treatment: How Do We Manage Antimicrobial Resistance? World Journal of Gastroenterology, 25, 1907-1912.
https://doi.org/10.3748/wjg.v25.i16.1907 |
| [32] | Suzuki, S., Gotoda, T., Kusano, C., et al. (2020) Seven-Day Vonoprazan and Low-Dose Amoxicillin Dual Therapy as First-Line Helicobacter pylori Treatment: A Multicentre Randomised Trial in Japan. Gut, 69, 1019-1026.
https://doi.org/10.1136/gutjnl-2019-319954 |
| [33] | Gotoda, T., Kusano, C., Suzuki, S., et al. (2020) Clinical Impact of Vonoprazan-Based Dual Therapy with Amoxicillin for H. pylori Infection in a Treatment-Naive Cohort of Junior High School Students in Japan. Journal of Gastroenterology, 55, 969-976. https://doi.org/10.1007/s00535-020-01709-4 |
| [34] | Sue, S., Kondo, M., Sato, T., et al. (2023) Vonoprazan and High-Dose Amoxicillin Dual Therapy for Helicobacter pylori First-Line Eradication: A Single-Arm, Interventional Study. JGH Open, 7, 55-60.
https://doi.org/10.1002/jgh3.12852 |
| [35] | Lin, Y.M., Xu, H.M., Yun, J.W., et al. (2022) The Efficacy of Vonoprazan Combined with Different Dose Amoxicillin on Eradication of Helicobacter pylori: An Open, Multi-center, Randomized Clinical Study. Annals of Translational Medicine, 10, Article 987. https://doi.org/10.21037/atm-22-4133 |
| [36] | Hu, Y., Xu, X., Ouyang, Y.B., et al. (2022) Optimization of Vonoprazan-Amoxicillin Dual Therapy for Eradicating Helicobacter pyloriInfection in China: A Prospective, Randomized Clinical Pilot Study. Helicobacter, 27, e12896.
https://doi.org/10.1111/hel.12896 |
| [37] | Chey, W.D., Mégraud, F., Laine, L., et al. (2022) Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology, 163, 608-619.
https://doi.org/10.1053/j.gastro.2022.05.055 |
| [38] | Kang, J., Kim, Y.J., Shim, T.S., et al. (2018) Risk for Car-diovascular Disease in Patients with Nontuberculous Mycobacteria Treated with Macrolide. Journal of Thoracic Disease, 10, 5784-5795. https://doi.org/10.21037/jtd.2018.09.145 |
| [39] | Horii, T., Suzuki, S., Takano, C., et al. (2021) Lower Impact of Vonoprazan-Amoxicillin Dual Therapy on Gut Microbiota for Helicobacter pylori Erad-ication. Journal of Gastroenterology and Hepatology, 36, 3314-3321.
https://doi.org/10.1111/jgh.15572 |
| [40] | Hu, Y., Xu, X., Ouyang, Y.B., et al. (2022) Altered Gut Microbiota and Short-Chain Fatty Acids after Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication. Frontiers in Cellular and Infection Microbiology, 12, Article 881968. https://doi.org/10.3389/fcimb.2022.881968 |
| [41] | Hu, Y., Xu, X., Ouyang, Y.B., et al. (2022) Analysis of Oral Microbiota Alterations Induced by Helicobacter pylori Infection and Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication. Helicobacter, 27, e12923.
https://doi.org/10.1111/hel.12923 |
| [42] | Katayama, Y., Toyoda, K., Kusano, Y., et al. (2017) Efficacy of Vonoprazan-Based Second-Line Helicobacter pylori Eradication Therapy in Patients for Whom Vonoprazan-Based First-Line Treatment Failed. Gut, 66, 752-753.
https://doi.org/10.1136/gutjnl-2016-312028 |
| [43] | Hojo, M., Asaoka, D., Takeda, T., et al. (2020) Randomized Controlled Study on the Effects of Triple Therapy Including Vonoprazan Or Rabeprazole for the Second-Line Treatment of Helicobacter pylori Infection. Therapeutic Advances in Gastroenterology, 13, 1-11. https://doi.org/10.1177/1756284820966247 |
| [44] | Zhou, L.Y., et al. (2022) Chinese National Clinical Practice Guideline on Helicobacter pylori Eradication Treatment. Chinese Journal of Digestion, 42, 745-756. |
| [45] | Murakami, K., Sato, R., Okimoto, T., et al. (2006) Effectiveness of Minocycline-Based Triple Therapy for Eradication of Helicobacter pylori Infection. Journal of Gastroenterology and Hepatology, 21, 262-267.
https://doi.org/10.1111/j.1440-1746.2006.04183.x |
| [46] | Yang, J.C., Lin, C.J., Wang, H.L., et al. (2015) High-Dose Dual Therapy Is Superior to Standard First-Line or Rescue Therapy for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology, 13, 895-905.E5.
https://doi.org/10.1016/j.cgh.2014.10.036 |
| [47] | Bi, H.X., Chen, X.X., Chen, Y.X., et al. (2022) Efficacy and Safety of High-Dose Esomeprazole-Amoxicillin Dual Therapy for Helicobacter pylori Rescue Treatment: A Mul-ticenter, Prospective, Randomized, Controlled Trial. Chinese Medical Journal, 135, 1707-1715. https://doi.org/10.1097/CM9.0000000000002289 |
| [48] | Sue, S., Shibata, W., Sasaki, T., et al. (2019) Ran-domized Trial of Vonoprazan-Based versus Proton-Pump Inhibitor-Based Third-Line Triple Therapy with Sitafloxacin for Helicobacter pylori. Journal of Gastroenterology and Hepatology, 34, 686-692. https://doi.org/10.1111/jgh.14456 |
| [49] | Saito, Y., Konno, K., Sato, M., et al. (2019) Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori. Cancers, 11, Article 116. https://doi.org/10.3390/cancers11010116 |
| [50] | Inokuchi, K., Mori, H., Matsuzaki, J., et al. (2022) Efficacy and Safety of Low-Dose Rifabutin-Based 7-Day Triple Therapy as a Third- or Later-Line Helicobacter pylori Eradication Regimen. Helicobacter, 27, e12900.
https://doi.org/10.1111/hel.12900 |
| [51] | Hirata, Y., Yamada, A., Niikura, R., et al. (2020) Efficacy and Safety of a New Rifabutin-Based Triple Therapy with Vonoprazan for Refractory Helicobacter pyloriInfection: A Pro-spective Single-Arm Study. Helicobacter, 25, e12719.
https://doi.org/10.1111/hel.12719 |
| [52] | Astruc, B., Jenkins, H. and Jenkins, R. (2017) Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects. Clinical and Translational Science, 10, 208-216.
https://doi.org/10.1111/cts.12452 |
| [53] | Kakiuchi, T., Matsuo, M., Endo, H., et al. (2023) Efficacy and Safety of Vonoprazan-Based Regimen for Helicobacter pylori Eradication Therapy in Japanese Adolescents: A Prospec-tive Multicenter Study. Journal of Gastroenterology, 58, 196-204. https://doi.org/10.1007/s00535-022-01942-z |
| [54] | Sugano, K. (2018) Vonoprazan Fumarate, a Novel Potas-sium-Competitive Acid Blocker, in the Management of Gastroesophageal Reflux Disease: Safety and Clinical Evidence to Date. Therapeutic Advances in Gastroenterology, 11, 1-14. https://doi.org/10.1177/1756283X17745776 |
| [55] | Saruta, Y., Watanabe, K., Tsuji, T., et al. (2023) Vonoprazan Poses No Additional Risk of Developing Clostridioides difficile Infection Compared to Proton Pump Inhibitors. Journal of Gastroenterology and Hepatology, 38, 940-947.
https://doi.org/10.1111/jgh.16169 |
| [56] | Miyamoto, S., Matsuno, Y., Kato, M., et al. (2017) Parietal Cell Pro-trusions and Dilated Oxyntic Glands from Use of Vonoprazan. American Journal of Gastroenterology, 112, 1899-1901. https://doi.org/10.1038/ajg.2017.364 |
| [57] | Yoshizaki, T., Morisawa, T., Fujinami, M., et al. (2021) Propensity Score Matching Analysis: Incidence and Risk Factors for “Stardust” Gastric Mucosa, a Novel Gastric Finding Potentially Induced by Vonoprazan. Alimentary Pharmacology & Therapeutics, 53, 94-102. https://doi.org/10.1111/apt.16151 |
